Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.4852W HIGH $18.57
Volume
1.37 M
Value Traded
20.15 M
Short % Float
15.91%
-6.86%Week
-5.55%1 Month
-20.37%3 Month
+19.37%6 Month
+57.5%5 Year
+57.5%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.82 B
EPS (TTM)
-3.89
P/E Ratio
-
Ent. Value
1.56 B
Total Shares
151.04 M
Float Shares
128.56 M
Insiders
14.89%
Institutions
91.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BHVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Biohaven Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Biohaven Ltd.
324Total events
11Upcoming
92Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseBHV-1300Corporate
Biohaven licenses MoDE pan IgG degraders to Ono in Japan and select Asian regions
Graves' diseasesource ↗
▲Partnership / LicenseOpakalimCorporate
Biohaven and SK Biopharmaceuticals enter strategic global licensing agreement for Kv7 platform and opakalim
focal epilepsysource ↗
▲IP Litigation RulingIP / Competition
Court enters judgment in trade secret misappropriation case
▲Partnership / LicenseBHV-1530Corporate
Clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab
▲Enrollment UpdateBHV-8000Trial
Enrollment in Phase 2/3 early Parkinson's disease trial with BHV-8000 continues to advance
early Parkinson's diseasesource ↗
▲Enrollment UpdateBHV-1510Trial
Enrollment advances in advanced endometrial cancer expansion cohort with BHV-1510 in combination with Libtayo
advanced endometrial cancersource ↗
▲IP Litigation RulingIP / Competition
Jury returns verdict in trade secret misappropriation case
▲Partnership / LicenseBHV-1530Corporate
Clinical supply agreement with Regeneron for BHV-1530 and cemiplimab combination
Solid tumorssource ↗
◆Trial InitiationBHV-1530Trial
Initiation of combination cohorts with anti-PD-1 therapy (cemiplimab)
Solid tumorssource ↗
▲Enrollment CompleteOpakalimTrial
Enrollment completed in pivotal Phase 2/3 study RISE3 for opakalim in focal epilepsy
refractory focal epilepsysource ↗
▲First Patient DosedBHV-1300Trial
First patient enrolled in pivotal Phase 3 trial of BHV-1300 for Graves' disease
Graves' diseasesource ↗
▲First Patient DosedBHV-8100Trial
First-in-Human dosing commenced with BHV-8100
systemic and central nervous system disorderssource ↗
▲Trial InitiationBHV-1300Trial
Initiated pivotal Phase 3 study for BHV-1300 in Graves' disease
Graves' diseasesource ↗
◆Trial InitiationBHV-1400Trial
Initiation of pivotal trial for BHV-1400 in IgA nephropathy
IgA nephropathysource ↗
▲Biomarker DataBHV-1300Clinical Data
Positive clinical biomarker and patient data for BHV-1300 in Graves' disease
Graves' diseasesource ↗
▲Biomarker DataBHV-1400Clinical Data
Positive clinical biomarker and patient data for BHV-1400 in IgA nephropathy
IgA nephropathysource ↗
◆Oral PresentationOpakalimPresentation
R&D Day presentation of proof-of-concept study results in IGE
idiopathic generalized epilepsysource ↗
▲Full ResultsOpakalimClinical Data
Results from randomized, double-blind, placebo-controlled proof-of-concept study of opakalim in IGE
idiopathic generalized epilepsy (IGE)source ↗
▲Topline ReadoutBHV-1530Clinical Data
Early Phase 1 data disclosed at R&D Day
Advanced solid tumorssource ↗
▲Oral PresentationOpakalimPresentation
Presented clinical data update with opakalim across multiple epilepsy types at R&D Day
multiple epilepsy typessource ↗
▲Full ResultsOpakalimClinical Data
OLE data: 54% of participants on opakalim 75 mg achieved ≥50% seizure reduction
focal epilepsysource ↗
▲Oral PresentationBHV-1300Presentation
Presented new patient data from Phase 1b study of BHV-1300 in Graves' disease
Graves' diseasesource ↗
▲Oral PresentationBHV-1400Presentation
Reported updated Phase 1b data from study of BHV-1400 in IgAN
IgA nephropathy (IgAN)source ↗
◆Topline ReadoutOpakalimClinical Data
Top-line results from first pivotal Phase 2/3 study in refractory focal epilepsy
refractory focal epilepsysource ↗
◆Topline ReadoutBHV-1400Clinical Data
Topline data from Phase 1 trial of BHV-1400 in IgAN expected in Q2 2026
IgA nephropathysource ↗
◆Topline ReadoutBHV-1300Clinical Data
Topline data from Phase 1 trial of BHV-1300 in Graves' disease expected in Q2 2026
Graves' diseasesource ↗
◆Oral PresentationPresentation
Biohaven presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Partnership / LicenseCorporate
Memorandum of understanding with KAUST for degrader discovery collaboration
◆Enrollment UpdateBHV-8000Trial
Patient enrollment continues in pivotal Phase 2/3 trial with BHV 8000
early Parkinson's diseasesource ↗
◆Oral PresentationPresentation
Biohaven management presentation at J.P. Morgan Healthcare Conference
▼Equity OfferingCorporate
Issued and sold 17.2 million common shares for net proceeds of $178.9 million
▲First Patient DosedBHV-1510Trial
Initiated subcutaneous administration with BHV-1510
TROP2-expressing carcinomassource ↗
▲Enrollment Completetaldefgrobep alfaTrial
Patient enrollment complete in Phase 2 study of taldefgrobep alfa in obesity
obesitysource ↗
▼Primary Endpoint MissedBHV-7000Clinical Data
Phase 2 proof-of-concept study did not meet primary endpoint
major depressive disordersource ↗
▲Full ResultsBHV-1510Clinical Data
Clinical safety and efficacy data for BHV-1510 in combination with cemiplimab presented at ESMO
advanced solid tumors (NSCLC, endometrial, urothelial, triple negative breast cancer)source ↗
◆Poster PresentationBHV-1510Presentation
Poster 252P: Phase 1 clinical trial of BHV-1510 in combination with cemiplimab at ESMO Immuno-Oncology Congress
advanced solid tumorssource ↗
●Oral PresentationBHV-1510Presentation
Presented data from BHV1510-101 trial at ESMO Immuno-Oncology Congress
TROP2-expressing carcinomassource ↗
Past FDA Catalysts and PDUFA Decisions
How BHVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | BHV-7000 | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C56 / 100
Pipeline Score
$973M
Pipeline Value
Overvalued
Valuation Signal
13
Drugs Scored
0.5x
rNPV / MCap
Top 10%
Micro Cap(rank 67 of 660)
Percentile Rank
Biohaven Ltd. carries a moderate pipeline score (56/100), with $3.2B risk-adjusted pipeline value, led by BHV-1400 in IgA Nephropathy (Phase 3), across $148B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BHV-1400 Small moleculeNCT07642050 | IgA Nephropathy | Phase 3 | NOT YET_RECRUITING | 440 | Oct 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every BHVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BHV-1530 | advanced or metastatic solid tumors | Phase 1 | 2026-09-28 | no dose-limiting toxicities and no FGFR inhibitor-class toxicitiesRead More | Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Mehta KishanDirector | Grant/Award | 68,693 68,693 held | $0.00 | 04/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BHVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 0.6 % (-45.5 %) | 26.48 M | 1.78 M | -61.57% ( -2.85 M) |
BHVN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BHVN ranks across every disease it competes in
Competitive Position is a premium feature
See how BHVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBHVN News
BHVN▲ +1.3%today
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
Biohaven has entered a strategic licensing agreement with Ono Pharma for the development and commercialization of its MoDE pan IgG degraders, including BHV-1300, in Japan and select Asian regions. The deal includes up to $100 million in payments, with BHV-1300 currently in Phase 3 for Graves' disease. This collaboration marks a significant milestone for Biohaven's innovative IgG degrader technology.
Read more →BHVNBiohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Biohaven's BHV-1530, a first-in-class FGFR3-directed antibody-drug conjugate, has been selected for an oral presentation at the EORTC-NCI-AACR Symposium 2026. The ongoing Phase 1 study has shown promising early clinical activity and a favorable safety profile. Additionally, Biohaven has begun enrolling patients for a combination study with cemiplimab, enhancing its therapeutic potential.
Read more →BHVN▲ +17.9%on this news
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
Biohaven and SK Biopharmaceuticals have entered a strategic global licensing agreement for Biohaven's Kv7 ion channel platform, including the lead candidate opakalim, which is in Phase 2/3 development for focal epilepsy. The deal could yield up to $795 million in payments and royalties for Biohaven, while providing SK Biopharmaceuticals with a new treatment option for epilepsy. This partnership aims to expedite the development and commercialization of opakalim, leveraging SK's established capabilities.
Read more →BHVN▲ +17.9%on this newsshared move
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
The U.S. District Court for Delaware has ruled in favor of Biohaven and Yale University in a trade secret misappropriation case against RA Capital and Avilar Therapeutics. The court formalized a $4 million award, reflecting the jury's findings of willful and malicious misappropriation of Yale's trade secret related to the MODA platform. This judgment follows a jury verdict delivered on July 24, 2026.
Read more →BHVNBiohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
Biohaven Ltd. reported significant advancements in its clinical pipeline, including the initiation of pivotal Phase 3 trials for BHV-1300 in Graves' disease and BHV-1400 in IgA nephropathy. The company also highlighted positive data for opakalim in epilepsy, with a focus on improving patient tolerability. Financially, Biohaven ended Q2 2026 with approximately $270.5 million in cash, despite reporting a net loss of $137.3 million.
Read more →BHVN▲ +5.8%on this newsshared move
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Biohaven Ltd. has appointed John Yetimoglu to its Board of Directors, effective immediately. Yetimoglu, founder of Infinitum, brings extensive experience in AI and technology investment, which aligns with Biohaven's focus on integrating advanced computational methods in drug development. His expertise is expected to strengthen the company's strategic oversight in these areas.
Read more →BHVNFederal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
A federal jury has ruled in favor of Biohaven Ltd. and Yale University in a case against Avilar Therapeutics and RA Capital, finding them guilty of willfully misappropriating a trade secret related to Yale's MODA platform. The jury awarded a total of $4 million in damages, confirming the claims of improper use of confidential information. Biohaven expressed gratitude for the jury's decision and emphasized its commitment to innovation and collaboration with academic institutions.
Read more →BHVNBiohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
Biohaven announced new clinical data on BHV-1530, an FGFR3-directed ADC, to be presented at the ESMO Congress 2026. Early Phase 1 data show tumor reductions in patients with FGFR3-altered and wild-type tumors. The drug demonstrates a favorable safety profile with no dose-limiting toxicities. A clinical supply agreement with Regeneron aims to evaluate BHV-1530 in combination with cemiplimab.
Read more →BHVN▼ -7.4%on this news
Biohaven Announces Scientific Leadership Transitions
Biohaven Ltd. has announced key leadership transitions aimed at enhancing drug innovation and collaborations. David Pirman has been promoted to Executive Vice President and Head of Discovery, while Bruce Car transitions to Chief Innovation Officer, focusing on external partnerships. Warren Volles has also been designated as an executive officer, continuing his legal leadership at the company.
Read more →BHVNBiohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
Biohaven has completed enrollment in its pivotal Phase 2/3 study, RISE3, evaluating opakalim for focal epilepsy. The study aims to provide top-line results in the second half of 2026. Preliminary data shows that 54% of participants experienced significant reductions in seizure frequency, with a favorable safety profile. The company emphasizes the need for new treatments for patients with uncontrolled seizures.
Read more →BHVN▼ -5.6%on this newsshared move
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Biohaven has initiated a pivotal Phase 3 trial for BHV-1300, the first MoDE extracellular protein degrader targeting Graves' disease. This innovative therapy aims to eliminate the disease-driving TSHR-IgG1 autoantibody rather than just treating symptoms. The trial represents a significant advancement in precision immunology, with potential implications for treating autoimmune diseases more effectively.
Read more →BHVNBiohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis...
Biohaven has announced the initiation of first-in-human dosing for BHV-8100, a novel oral pyruvate kinase M2 modulator designed to target metabolic and immune dysfunction. The drug aims to improve energy homeostasis in patients suffering from various neurodegenerative and retinal diseases. Effective in enhancing ATP generation, BHV-8100 was validated through preclinical testing, and a Phase 1 study has begun in healthy participants to assess its safety and pharmacokinetics. The company believes this treatment could provide significant benefits for patients with conditions such as Alzheimer's disease and retinitis pigmentosa.
Read more →BHVN▲ +12.1%on this newsshared move
Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
Biohaven Ltd. has announced positive results from its clinical trials involving its proprietary MoDE and TRAP degrader platforms. The data, presented at the 2026 Yale Innovation Summit, highlights the effectiveness of BHV-1300 in treating Graves' disease and BHV-1400 for IgA nephropathy. These findings suggest significant advancements in the treatment of autoimmune diseases.
Read more →BHVN▲ +12.1%on this newsshared move
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2 7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
Biohaven has reported promising new clinical data on opakalim, a selective Kv7.2 7.3 channel activator, for treating epilepsy. In a randomized trial for idiopathic generalized epilepsy, opakalim demonstrated a three-fold increase in the median time to the second seizure compared to placebo. An ongoing open-label extension study showed favorable results for patients with focal epilepsy, with over 54% achieving a significant reduction in seizure frequency. Opakalim's tolerability profile is notably better than other antiseizure therapies, with a low incidence of adverse central nervous system events.
Read more →BHVN▲ +6.6%on this news· ran to +19% by day 1shared move
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a...
Biohaven Ltd. has reported new clinical data for Opakalim, a selective Kv7.2/7.3 channel activator, demonstrating promising results in seizure control for idiopathic generalized epilepsy (IGE). The treatment offers a favorable tolerability profile, showing zero rates of common central nervous system side effects reported with other antiseizure medications. Additionally, high completion rates in ongoing studies reflect strong confidence among participants. However, challenges with enrollment have prevented reaching the intended study sample size, raising questions about the robustness of the findings.
Read more →BHVNBiohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
Biohaven Ltd. reported its Q1 2026 financial results, highlighting plans for pivotal clinical trials for BHV-1300 and BHV-1400. The company aims to advance its innovative therapies in immunology, neuroscience, and oncology. Despite a net loss of $130.5 million, Biohaven shows optimism with strategic milestones and reduced R&D expenses.
Read more →BHVNBiohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline...
Biohaven has announced that enrollment for its Phase 2 study of taldefgrobep alfa, a myostatin-activin pathway inhibitor for obesity, has been completed. The study is designed to evaluate the efficacy and tolerability of the drug administered as once-weekly and once-monthly doses. Topline data from this proof-of-concept study is anticipated in the second half of 2026. Previous studies have shown that taldefgrobep can reduce body fat and increase lean muscle mass, suggesting it may be an important treatment option in managing obesity.
Read more →BHVN▼ -9.7%on this news
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
Biohaven Ltd. reported its financial results for Q4 and full year 2025, highlighting advancements in its therapeutic pipeline, particularly in immunology and epilepsy treatments. The company emphasized its innovative degrader platform and promising data from its Kv7 program for focal epilepsy. Despite significant losses, Biohaven is focused on strategic cost optimization and prioritizing late-stage clinical programs.
Read more →BHVN▲ +6.6%on this news
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using Biohaven's proprietary...
Biohaven Ltd. showcased its progress and positive early patient data at the 44th Annual J.P. Morgan Healthcare Conference. The company reported successful initial dosing in its obesity program with a dual-action therapy and highlighted early clinical results from its BHV-1400 degrader for IgA nephropathy, showing rapid symptom resolution. Additionally, BHV-1300 exhibited significant reductions in IgG for Graves' disease. Biohaven is set to advance multiple programs targeting high unmet needs in 2026.
Read more →About Biohaven Ltd.
Headquarters215 CHURCH STREET, NEW HAVEN, CT, 06510
Founded2022
BIOPHARMAWATCH ELITE PLUS
Trade the next BHVN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime